95 related articles for article (PubMed ID: 36999235)
1. Circulating CD22+/CD19-/CD24- progenitors and CD22+/CD19+/CD24- mature B cells: Diagnostic pitfalls for minimal residual disease detection in B-lymphoblastic leukemia.
Zhou T; Karrs J; Ho T; Doverte A; Kochenderfer JN; Shah NN; Yuan CM; Wang HW
Cytometry B Clin Cytom; 2023 Jul; 104(4):294-303. PubMed ID: 36433814
[TBL] [Abstract][Full Text] [Related]
2. Clinical significance of end of induction measurable residual disease monitoring in B-cell acute lymphoblastic leukemia: A single center experience.
Arunachalam AK; Selvarajan S; Mani T; Janet NB; Maddali M; Lionel SA; Kulkarni U; Korula A; Aboobacker FN; Abraham A; George B; Balasubramanian P; Mathews V
Cytometry B Clin Cytom; 2023 Nov; 104(6):440-452. PubMed ID: 37555390
[TBL] [Abstract][Full Text] [Related]
3. Comparison of Measurable Residual Disease in Pediatric B-Lymphoblastic Leukemia Using Multiparametric Flow Cytometry and Next-Generation Sequencing.
Hwang SM; Oh I; Kwon SR; Lee JS; Seong MW
Ann Lab Med; 2024 Jul; 44(4):354-358. PubMed ID: 38237930
[TBL] [Abstract][Full Text] [Related]
4. Multiparameter flow cytometry and ClonoSEQ correlation to evaluate precursor B-lymphoblastic leukemia measurable residual disease.
Momen N; Tario J; Fu K; Qian YW
J Hematop; 2023 Jun; 16(2):85-94. PubMed ID: 38175444
[TBL] [Abstract][Full Text] [Related]
5. Updates on lymphoblastic leukemia/lymphoma classification and minimal/measurable residual disease analysis.
Kovach AE; Wood BL
Semin Diagn Pathol; 2023 Nov; 40(6):457-471. PubMed ID: 37953192
[TBL] [Abstract][Full Text] [Related]
6. Advances in Monitoring and Prognostication for Lymphoma by Flow Cytometry.
Singh AP; Courville EL
Clin Lab Med; 2023 Sep; 43(3):351-361. PubMed ID: 37481316
[TBL] [Abstract][Full Text] [Related]
7. Deciphering stage 0 hematogones by flow cytometry in follow-up bone marrow samples of pediatric B-Acute lymphoblastic leukemia cases: A potential mimicker of residual disease after anti CD19 therapy.
Ramalingam TR; Vaidhyanathan L; Muthu A; Swaminathan VV; Uppuluri R; Raj R
Cytometry B Clin Cytom; 2024 Mar; 106(2):92-98. PubMed ID: 38243626
[TBL] [Abstract][Full Text] [Related]
8. Maturational dyssynchrony in benign B-cell precursors following lymphocyte depleting chemotherapy: A potential pitfall for B-lymphoblastic leukemia minimal/measurable residual disease (MRD) flow cytometry analysis.
Placek A; Lockhart B; Miller KP; Wertheim GB; Maude SL; Wood BL; Kovach AE
Cytometry B Clin Cytom; 2024 Mar; 106(2):138-141. PubMed ID: 38247200
[No Abstract] [Full Text] [Related]
9. Bulk lysis procedures alter target cell population counts.
Rico LG; Salvia R; Ward MD; Petriz J
Cytometry A; 2024 May; ():. PubMed ID: 38722042
[TBL] [Abstract][Full Text] [Related]
10. Clinical Flow Cytometry Analysis in the Setting of Chronic Myeloid Neoplasms and Clonal Hematopoiesis.
El Hussein S; Loghavi S
Clin Lab Med; 2023 Sep; 43(3):411-426. PubMed ID: 37481320
[TBL] [Abstract][Full Text] [Related]
11. The Evolving Landscape of Flowcytometric Minimal Residual Disease Monitoring in B-Cell Precursor Acute Lymphoblastic Leukemia.
Verbeek MWC; van der Velden VHJ
Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38732101
[TBL] [Abstract][Full Text] [Related]
12. 19-color, 21-Antigen Single Tube for Efficient Evaluation of B- and T-cell Neoplasms.
Chan A; Gao Q; Roshal M
Curr Protoc; 2023 Sep; 3(9):e884. PubMed ID: 37725693
[TBL] [Abstract][Full Text] [Related]
13. Highly sensitive single tube B-lymphoblastic leukemia/lymphoma minimal/measurable residual disease test robust to surface antigen directed therapy.
Gao Q; Liu Y; Aypar U; Baik J; Londono D; Sun X; Zhang J; Zhang Y; Roshal M
Cytometry B Clin Cytom; 2023 Jul; 104(4):279-293. PubMed ID: 36999235
[TBL] [Abstract][Full Text] [Related]
14. 15-color highly sensitive flow cytometry assay for post anti-CD19 targeted therapy (anti-CD19-CAR-T and blinatumomab) measurable residual disease assessment in B-lymphoblastic leukemia/lymphoma: Real-world applicability and challenges.
Chatterjee G; Dhende P; Raj S; Shetty V; Ghogale S; Deshpande N; Girase K; Patil J; Kalra A; Narula G; Dalvi K; Dhamne C; Moulik NR; Rajpal S; Patkar NV; Banavali S; Gujral S; Subramanian PG; Tembhare PR
Eur J Haematol; 2024 Jan; 112(1):122-136. PubMed ID: 37706583
[TBL] [Abstract][Full Text] [Related]
15. A novel flow cytometric assay for detection of residual disease in patients with B-lymphoblastic leukemia/lymphoma post anti-CD19 therapy.
Cherian S; Miller V; McCullouch V; Dougherty K; Fromm JR; Wood BL
Cytometry B Clin Cytom; 2018 Jan; 94(1):112-120. PubMed ID: 27598971
[TBL] [Abstract][Full Text] [Related]
16. B-lineage antigens that are useful to substitute CD19 for minimal residual disease monitoring in B cell precursor acute lymphoblastic leukemia after CD19 targeting.
Mikhailova E; Itov A; Zerkalenkova E; Roumiantseva J; Olshanskaya Y; Karachunskiy A; Novichkova G; Maschan M; Popov A
Cytometry B Clin Cytom; 2022 Sep; 102(5):353-359. PubMed ID: 35796438
[TBL] [Abstract][Full Text] [Related]
17. Monitoring minimal/measurable residual disease in B-cell acute lymphoblastic leukemia by flow cytometry during targeted therapy.
Liu Z; Li Y; Shi C
Int J Hematol; 2021 Mar; 113(3):337-343. PubMed ID: 33502735
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
